UCB Spotlights Bimekizumab And Other Later-Stage R&D Projects
Belgium-headquartered UCB has a group of antibody-based products in mid to late-stage clinical studies which will be competing in the dermatology/immune disorders marketplace in the next few years.
You may also be interested in...
With Celgene's psoriasis pill Otezla for sale and AbbVie in the midst of launching a new competitor to blockbuster brands like Novartis' Cosentyx and J&J's Tremfya, investors will be focused on the category as drug makers report second quarter financials.
The EMA’s CHMP cited concerns over cardiovascular side effects as the reason why it took a negative stance on Evenity’s use in the EU for treating severe osteoporosis.
Keeping Track: Novartis Scores Big Ahead Of US Memorial Day With Approvals For Gene Therapy Zolgensma, Oncologic Piqray
The latest drug development news and highlights from our US FDA Performance Tracker.